Dyslipidaemia among diabetic patients with ischemic stroke in a Chinese hospital

Chinese Medical Journal

Volumn 122, Issue 21, 2009, Pages 2567-2572

  Wang, Shao Hua ^a   Sun, Zi Lin ^a   Ruan, Xiong Zhong ^b   Guo, Yi Jing ^a   Wang, Yao ^a   Jin, Hui ^a   Yuan, Yang ^a   Wei, Qiong ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Diabetes; Dyslipidaemia; High density lipoprotein cholesterol; Low density lipoprotein cholesterol; Stroke, ischemic; Triglyceride

Indexed keywords

ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHINA; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DISEASE CONTROL; DISEASE DURATION; DYSLIPIDEMIA; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SEX DIFFERENCE; STROKE PATIENT;

AGED; AGED, 80 AND OVER; CHINA; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; MALE; MIDDLE AGED; STROKE;

EID: 73449088762     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.21.008     Document Type: Article

References (23)

1. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, et al. Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Stroke 2003; 34: 623-631.
2. Harmsen P, Rosengren A, Tsipogianni A, Wilhelmsen L. Risk factors for stroke in middle-aged men in Goteborg, Sweden. Stroke 1990; 21: 223-229.
3. Kissela BM, Khoury J, Kleindorfer D, Woo D, Schneider A, Alwell K, et al. Epidemiology of ischemic stroke in patients with diabetes: the Greater Cincinnati/Northern Kentucky Stroke Study. Diabetes Care 2005; 28: 355-359.
4. Jorgensen H, Nakayama H, Raaschou HO, Olsen TS. Stroke in patients with diabetes: the Copenhagen Stroke Study. Stroke 1994; 25: 1977-1984.
5. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
6. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004; 27 (Suppl 1): s68-s71.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
8. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus. Circulation 2007; 115: 114-126.
9. American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care 2007; 30 (Suppl 1): s4-s41.
10. Broderick JP, Phillips SJ, O'Fallon WM, Frye RL, Whisnant JP. Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. Stroke 1992; 23: 1250-1256.
11. Boden-Albala B, Sacco RL, Lee HS, Grahame-Clarke C, Rundek T, Elkind MV, et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study. Stroke 2008; 39: 30-35.
12. Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26: 2713-2721.
13. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
14. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117-125.
15. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA, et al. Risk of stroke in people with type 2 diabetes in the UK: a study using the General Practice Research Database. Diabetologia 2006; 49: 2859-2865.
16. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Predictors of stroke in middle aged patients with non-insulin-dependent diabetes. Stroke 1996; 27: 63-68.
17. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 2008; 196: 489-496.
18. Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002; 106: 2526-2529.
19. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2002; 358: 2026-2033.
20. Walldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med 2006; 259: 259-266.
21. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364: 937-952.
22. Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, et al. Plasma lipid profile and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 2003; 34: 623-631.
23. Sacco RL. Newer risk factors for stroke. Neurology 2001; 57: s31-s34.